1. Biotech IPO bonanza: Legend Biotech, Forma Therapeutics, Repare — COVID-19 could slow progress in reducing cancer death, NCI warns — ASCO 2020 news from Merck, AstraZeneca, Pfizer, more — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Endo division is done-

Discussion in 'Serono' started by anonymous, Nov 18, 2017 at 4:46 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    So they have finally killed off Saizen presence in the US, made cuts across the board in Fertility and Serostim, telling reps at 12PM, that at 5PM, you are no longer with the company. Sounds like this company is in some deep financial trouble when you lay off folks effective immediately.

    How much longer before they are done with Endo completely, and pivot to MS and Onc only?
     

  2. anonymous

    anonymous Guest

    With Richard Smith leading Endo and Fertility it will not be long.
     
  3. anonymous

    anonymous Guest

    Any serious thoughts on how much longer this division will be around?
     
  4. anonymous

    anonymous Guest

    Decades !
     
  5. anonymous

    anonymous Guest

    Move along troll... all good here... minor tweaks that needed to be done...
     
  6. Deliahp

    Deliahp new user

    Joined:
    Dec 26, 2017
    Messages:
    3
    Likes Received:
    0
    Tweaks NOt minor
     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest

    It's not just R Smith that needs to be gone. The other leadership does not have enough experience. They need to be gone too.
     
  9. anonymous

    anonymous Guest

    Serostim is a 20 year old drug. The idea of investing in an HIV & aging study was encouraging. After the layoffs and deciding to discontinue the study the signs are very clear about the future. All corporate investment is going towards other therapeutic areas - oncology, immunology and neurology. This isn’t rocket science.
     
  10. anonymous

    anonymous Guest

    R Smith should have never been hired here. My contacts at Novartis tell me he was pushed out due to his limited strategic thinking capability and inability to inspire. He accomplished nothing while here so his departure was not a surprise
     
  11. anonymous

    anonymous Guest

    Clearly a bone to pick here as you have torched him on 2 threads... don’t know about Novartis but the guy was better than anything we have had here in a long time (C.M.—- come on!). and is gone because he didn’t buy into the bullshit amateur culture he stepped into with the shenanigans of a week President and tyrant HR and finance Witch... this place is a joke and has been for a long time and at least he wouldnt play ball with the shenanigans... I would work for him tomorrow if he lands.. at least he understands specialty and cares about people...